XOL-1 regulates developmental timing by modulating the H3K9 landscape in C. elegans early embryos.
Eshna JashAnati Alyaa AzharHector MendozaZoey M TanHalle Nicole EscherDalia S KaufmanGyörgyi CsankovszkiPublished in: PLoS genetics (2024)
Sex determination in the nematode C. elegans is controlled by the master regulator XOL-1 during embryogenesis. Expression of xol-1 is dependent on the ratio of X chromosomes and autosomes, which differs between XX hermaphrodites and XO males. In males, xol-1 is highly expressed and in hermaphrodites, xol-1 is expressed at very low levels. XOL-1 activity is known to be critical for the proper development of C. elegans males, but its low expression was considered to be of minimal importance in the development of hermaphrodite embryos. Our study reveals that XOL-1 plays an important role as a regulator of developmental timing during hermaphrodite embryogenesis. Using a combination of imaging and bioinformatics techniques, we found that hermaphrodite embryos have an accelerated rate of cell division, as well as a more developmentally advanced transcriptional program when xol-1 is lost. Further analyses reveal that XOL-1 is responsible for regulating the timing of initiation of dosage compensation on the X chromosomes, and the appropriate expression of sex-biased transcriptional programs in hermaphrodites. We found that xol-1 mutant embryos overexpress the H3K9 methyltransferase MET-2 and have an altered H3K9me landscape. Some of these effects of the loss of xol-1 gene were reversed by the loss of met-2. These findings demonstrate that XOL-1 plays an important role as a developmental regulator in embryos of both sexes, and that MET-2 acts as a downstream effector of XOL-1 activity in hermaphrodites.
Keyphrases
- poor prognosis
- transcription factor
- single cell
- tyrosine kinase
- gene expression
- genome wide
- long non coding rna
- genome wide identification
- dendritic cells
- immune response
- regulatory t cells
- quality improvement
- mesenchymal stem cells
- copy number
- heat shock
- photodynamic therapy
- solid phase extraction
- fluorescence imaging
- type iii